Want to see HK:0874 full AI Analyst Report?
Top Page
Guangzhou Baiyunshan Pharmaceutical Holdings Company
(0874)
Select Model
Select Model
Rating:56Neutral
Price Target:
HK$14.50
â–¼(-22.67% Downside)
Action:Reiterated
Date:04/28/26
The score is held back primarily by weakening cash generation and margin compression despite strong revenue growth, alongside a bearish technical setup below key moving averages. These risks are partly offset by an attractive valuation (low P/E) and a high dividend yield.
Positive Factors
Robust revenue growth
Sustained ~77% TTM revenue growth signals durable demand for the company’s products and effective commercial execution. Over the next several months this top-line expansion can support scale economies, strengthen negotiating leverage with suppliers, and fund R&D or product launches if cash conversion stabilizes.
Negative Factors
Weakening cash generation
The shift to negative FCF in 2025 and only modest positive FCF in TTM signals durable stress in cash conversion. Persistent weak cash flow limits capacity for capex, acquisitions, dividends, or debt reduction and increases reliance on external financing, raising financing risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Robust revenue growth
Sustained ~77% TTM revenue growth signals durable demand for the company’s products and effective commercial execution. Over the next several months this top-line expansion can support scale economies, strengthen negotiating leverage with suppliers, and fund R&D or product launches if cash conversion stabilizes.
Read all positive factors
Guangzhou Baiyunshan Pharmaceutical Holdings Company (0874) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$37.96B
Dividend Yield7.15%
Average Volume (3M)908.48K
Price to Earnings (P/E)12.0
Beta (1Y)0.65
Revenue Growth7.32%
EPS Growth12.84%
CountryHK
Employees27,057
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.81
Shares Outstanding219,900,000
10 Day Avg. Volume928,235
30 Day Avg. Volume908,476
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)0.68
Price to Sales (P/S)0.33
P/FCF Ratio-27.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$23.00Price Target Upside22.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.89
Revenue Forecast (FY)HK$81.51B
Guangzhou Baiyunshan Pharmaceutical Holdings Company Business Overview & Revenue Model
Company Description
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GBPHCL) is a comprehensive pharmaceutical enterprise focused on the research, development, production, and distribution of a wide array of medical products. These offerings span traditi...
How the Company Makes Money
The company makes money primarily by (1) selling medicines and healthcare products it manufactures and (2) distributing pharmaceuticals and related products through wholesale and retail channels. Revenue from manufacturing is generated when Baiyun...
Guangzhou Baiyunshan Pharmaceutical Holdings Company Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
66
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 78.22B | 77.66B | 74.99B | 75.52B | 70.79B | 69.01B |
| Gross Profit | 12.54B | 12.52B | 12.52B | 14.19B | 13.28B | 13.23B |
| EBITDA | 4.00B | 3.95B | 4.90B | 6.49B | 6.22B | 5.82B |
| Net Income | 2.95B | 2.98B | 2.84B | 4.06B | 3.97B | 3.72B |
Balance Sheet | ||||||
| Total Assets | 89.46B | 84.55B | 81.68B | 78.59B | 74.67B | 66.12B |
| Cash, Cash Equivalents and Short-Term Investments | 12.29B | 23.81B | 22.72B | 21.31B | 22.56B | 22.38B |
| Total Debt | 17.04B | 20.70B | 12.37B | 11.70B | 11.43B | 9.92B |
| Total Liabilities | 47.71B | 43.40B | 43.91B | 41.91B | 41.03B | 34.79B |
| Stockholders Equity | 39.43B | 37.80B | 35.90B | 34.92B | 32.07B | 29.06B |
Cash Flow | ||||||
| Free Cash Flow | 666.92M | -954.34M | 2.31B | 2.48B | 5.62B | 4.42B |
| Operating Cash Flow | 1.91B | 253.50M | 3.44B | 4.10B | 7.00B | 5.67B |
| Investing Cash Flow | -6.76B | -3.81B | -5.96B | -3.11B | -7.25B | -931.57M |
| Financing Cash Flow | 2.03B | -98.13M | -1.01B | -1.98B | 45.95M | -1.49B |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Technical Analysis
Neutral
18.75
Price Trends
15.31
Negative
16.37
Negative
17.20
Negative
Market Momentum
-0.02
Negative
53.66
Neutral
85.76
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0874, the sentiment is Neutral. The current price of 18.75 is above the 20-day moving average (MA) of 14.88, above the 50-day MA of 15.31, and above the 200-day MA of 17.20, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 53.66 is Neutral, neither overbought nor oversold. The STOCH value of 85.76 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0874.
Guangzhou Baiyunshan Pharmaceutical Holdings Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$28.27B | 13.73 | 13.95% | 4.09% | 1.48% | -1.55% | |
61 Neutral | HK$29.03B | 17.50 | 8.65% | 2.26% | 10.00% | -7.54% | |
60 Neutral | HK$18.00B | 14.61 | 7.26% | 3.13% | 5.48% | -49.67% | |
58 Neutral | HK$66.44B | 18.02 | 7.19% | 1.69% | 1.52% | 22.54% | |
58 Neutral | HK$28.27B | 6.41 | 7.98% | 2.95% | 4.66% | 20.76% | |
56 Neutral | HK$37.96B | 12.03 | 7.70% | 7.15% | 7.32% | 12.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
15.30
-1.61
-9.50%
HK:0867
China Medical System Holdings
12.35
-0.41
-3.20%
HK:1513
Livzon Pharmaceutical Group
26.04
-4.64
-15.13%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
16.42
-0.33
-1.98%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.55
-0.49
-9.74%
HK:0512
Grand Pharmaceutical Group Limited
5.12
-3.91
-43.28%
Guangzhou Baiyunshan Pharmaceutical Holdings Company Corporate Events
Baiyunshan Pharma Sets Out Board Line-up and Committee Roles
May 29, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has announced the current composition of its board of directors, which includes six executive directors, one non-executive director and four independent non-executive directors, led by c...
Guangzhou Baiyunshan Sets Final 2025 Dividend and Tax Terms for H-Share Investors
May 29, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, a major player in the pharmaceutical and healthcare products sector, operates through H shares listed in Hong Kong and attracts a mix of mainland and overseas investors. Its business is...
Guangzhou Baiyunshan Shareholders Approve All AGM Resolutions and Board Changes
May 29, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited reported that its 2025 annual general meeting was held on 29 May 2026 in Guangzhou, with the session chaired by board chairman Li Xiaojun. The meeting was conducted in compliance with PR...
Guangzhou Baiyunshan Unit Sells RMB1 Billion in Receivables in Ongoing Securitisation Drive
May 22, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company, via its subsidiary GP Corp., has been actively managing its receivables through structured asset-backed schemes with Industrial Securities Asset Management, monetising large portfolios of accou...
Guangzhou Baiyunshan Appoints Liu Hong as Employee Representative Director to New Board
May 15, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings has named 37-year-old senior engineer Liu Hong as the employee representative director for its tenth board, following an employee representative meeting held under Chinese company law and the firm’...
Guangzhou Baiyunshan Pharma Sets Vote on New Three-Year Board Line-Up
May 7, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings has announced that the term of its ninth board is ending and that shareholders will vote on a new, tenth board at the 2025 annual general meeting. The proposed board will comprise eleven directors, incl...
Guangzhou Baiyunshan Sets 2025 AGM to Vote on Profit Distribution and Director Pay
May 7, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has called its 2025 annual general meeting for 29 May 2026 in Guangzhou, with shareholders able to vote both on-site and online for A shares. The board-led meeting will review the 2025 a...
Baiyunshan Q1 Revenue Rises as Profit Margins Narrow and Cash Outflows Ease
Apr 27, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings reported first-quarter 2026 operating revenue of RMB23.28 billion, up 3.58% year on year, while net profit attributable to shareholders slipped 2.06% to RMB1.78 billion as total profit edged down 1.04%....
Guangzhou Baiyunshan Pharma Sets Board Meeting to Review Q1 2026 Results
Apr 14, 2026
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited has scheduled a board meeting for 27 April 2026 in Guangzhou, where directors will review and approve the unaudited financial results for the three months ended 31 March 2026. The sessio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.